Feedback PLC - Trading Update
The information contained within this announcement is deemed by the Company to constitute inside information pursuant to Article 7 of EU Regulation 596/2014 as it forms part of
Feedback plc
Trading Update
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, provides an unaudited trading update for the year-ended
Revenue for the Period remained flat at c.
Significant national opportunity
The Company continues to pursue a potential national contract opportunity with NHSE for its Bleepa technology, following the ongoing success of its pilot with QVH. Based on recent conversations, whilst it is outside of the Company's control, the Company is hopeful of a decision around the calendar year end once NHSE and HM Treasury have concluded their evaluation. In the meantime, the Company has been encouraged to continue to build the evidence base by increasing the scale of its deployment in
Strong progress in integration with NHS interfaces demonstrates ability to scale
During the Period the Company completed key integrations to further optimise and increase the reach of our pathways and support adoption. These included integration into the NHS e-Referral Service, which captures GP referrals: this has already resulted in a tenfold increase in the number of GP practices referring into Bleepa in the first few weeks. Additionally, integration with Patients Know Best allows communication with patients via the NHS App, reducing administrative costs and friction of patient access to the clinical pathways, while integration with Evolve Electronic Medical Record automates backend document management within the Queen Victoria Hospital in
The Company has also released the latest generation of Bleepa, version 1.7, which alongside a new user interface based on frontline user feedback includes enhancements around data reporting, security and pathway automation features that reduce the administrative burden of delivering the clinical pathways, increasing scalability and reducing future operating costs of these pathways for NHS customers. The Company believes that evidencing these benefits will further support pending NHSE decisions and increase the likelihood of a contract award.
Proven productivity enhancing solutions
The Company is pleased to report that it continues to see strong growth and performance across the clinical pathways in
NHS need remains
NHS waitlists remain stubbornly high. Since the Referral to Treatment wait list peaked in
The need for a transformational alternative approach is clear. In addition to central NHSE discussions the Company continues dialogue with a number of NHS regions around direct opportunities to explore our offering. There is a growing appreciation that the NHS needs a new approach and that the asynchronous pathway model that Bleepa delivers is the solution.
Dr
--Ends--
Enquiries:
|
Feedback plc |
+44 (0) 20 3997 7634 |
|
|
|
|
Panmure Liberum Limited (NOMAD and Broker) |
+44 (0)20 7886 2500 |
|
|
|
|
Walbrook PR Ltd; |
Tel: 020 7933 8780 or feedbackplc@walbrookpr.com |
|
|
07748 325 236 or 07407 020 470 |
About Feedback plc
Feedback plc is the strategic partner to unlock productivity in health and care through digital connectivity and asynchronous collaboration. With proven expertise in system integration, we enable teams to work flexibly, share information securely, and deliver care more efficiently.
Bleepa® is an award-winning collaboration platform that improves the quality and productivity of patient pathways enabling health and care organisations to hit targets with their existing clinical workforce. We achieve this by connecting digital infrastructure across systems, enabling asynchronous working, reducing geographic barriers and removing unnecessary appointments.
Bleepa supports the shift from analogue to digital and from hospital to community-based care, by uniting essential data and teams to enhance clinical decision making and enable better coordinated care.
The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE